Antibiotic Pipeline Profile: Narrowing The Spectrum Of Drug Activity
Executive Summary
Development is most advanced in C. difficile infection, but US FDA's exploration of pathways to expedite single pathogen treatments could spur earlier-stage QIDP projects targeting Staphylococcus and Pseudomonas species.
You may also be interested in...
Polyphor Pursues Promise Of Inhaled Antibiotics To Tackle Lung Infections
An IMI-backed consortium is developing inhaled formulations of the privately held Swiss company's murepavadin and Novartis's tobramycin to reduce infections suffered by bronchiectasis and cystic fibrosis patients.
Actelion Setback Ahead Of J&J Deal Closure
A setback for Actelion – and Johnson & Johnson – as it reports mixed Phase III data for the Clostridium difficile treatment candidate cadazolid.
Flexible 'Menu' Of Antibacterial Development Options Suggested By US FDA Panel
FDA should consider allowing sponsors in challenging area of single species antibacterials more flexibility in study designs, advisory committee suggests, despite disagreement over approaches such as animal models and non-inferiority trials.